XM does not provide services to residents of the United States of America.
B
B

Bunzl

News

Barclays, Mips AB, Novo Nordisk

EUROPE RESEARCH ROUNDUP-Barclays, Mips AB, Novo Nordisk July 19 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Barclays, Mips AB and Novo Nordisk on Friday. HIGHLIGHTS * Barclays BARC.L : Jefferies raises target price to 341p from 335p * Mips AB MIPS.ST : Jefferies raises to buy from hold * Novo Nordisk NOVOB.CO : HSBC raises target price to DKK 1150 from DKK 1030 * Spectris SXS.L : HSBC raises target price to 3750p from 3425p * S
A
A
B
B
B
B
B
C
D
E
E
E
G
H
H
H
K
S
S
S
T
A
A

Adidas, Spirax Group, Stroeer

EUROPE RESEARCH ROUNDUP-Adidas, Spirax Group, Stroeer July 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas, Spirax Group and Stroeer, on Wednesday. HIGHLIGHTS * Adidas AG ADSGn.DE : JP Morgan raises target price to EUR 260 from EUR 250 * J D Wetherspoon JDW.L : Jefferies raises target price to 1,000p from 925p * Spirax Group SPX.L : HSBC raises to hold from reduce * Stroeer SAXG.DE : HSBC raises target price to EUR 79 fro
A
A
A
A
A
B
B
C
D
D
E
E
E
F
F
G
R
S
S
U
A
A
E
E
R
S
U

Bunzl, Relx, Rolls-Royce

EUROPE RESEARCH ROUNDUP-Bunzl, Relx, Rolls-Royce July 4 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Bunzl, Relx and Rolls-Royce, on Thursday. HIGHLIGHTS * Biomerieux BIOX.PA : Midcap raises to buy from hold * Bunzl BNZL.L : HSBC raises to buy from hold * Hennes & Mauritz HMB.ST : HSBC raises to buy from hold * Relx REL.L : Citigroup raises target price to 3525p from 3300p * Rolls-Royce RR.L : Barclays raises target price to 495p
A
A
A
B
B
G
G
G
H
H
L
L
M
N
N
R
S
S
T
U
U
W
A
H
A
P
R
R
W

Adyen, AstraZeneca, Auto Trader

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri
3
A
A
A
B
C
C
C
E
E
E
G
H
R
S
S
V
A
A
A
A
A
B
N
N
S

Bechtle AG, Centrica, Clariant AG

EUROPE RESEARCH ROUNDUP-Bechtle AG, Centrica, Clariant AG July 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bechtle AG, Centrica and Clariant AG, on Monday. HIGHLIGHTS * Akzo Nobel NV AKZO.AS : Goldman Sachs cuts to sell from neutral * Bechtle AG BC8G.DE : Exane BNP Paribas cuts to underperform from neutral * Centrica CNA.L : Berenberg raises to buy from hold * Clariant AG CLN.S : Goldman Sachs raises to buy from neutral * Fin
A
A
A
A
B
B
B
C
C
C
D
D
H
H
P
S
S
A
A
F
J

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.